K Hemminki1, X Li, J Sundquist, K Sundquist. 1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.hemminki@dkfz.de
Abstract
BACKGROUND: Patients diagnosed with Crohn disease (CD) are known to be at an increased risk of bowel cancers and lymphoma. CD is an autoimmune disease and we hypothesize that the patients are predisposed to a wider spectrum of cancers. PATIENTS AND METHODS: A CD research database was constructed by identifying hospitalized CD patients from the Hospital Discharge Register and cancer patients from the Swedish Cancer Registry. Follow-up of 21 788 CD patients first hospitalized during the years 1964-2004 identified 1424 cancer cases. Standardized incidence ratios (SIRs) were calculated by comparing cancers in CD patients with subjects without CD. RESULTS: In addition to the known sites, many additional sites were in excess in CD patients. These included liver, pancreatic, lung, prostate, testicular, kidney and skin (squamous cell) cancers; nonthyroid endocrine tumors and leukemia. The previously established sites showed the highest SIRs; however, SIRs >2.0 were noted for the novel sites of the liver, testis and kidney. For testicular cancer, the SIR of seminoma was 2.74. Cancer risks were influences by age at first hospitalization for CD but whether the age effects were increasing or decreasing depending on the cancer type. CONCLUSIONS: This large study identified many novel subsequent cancers in CD patients.
BACKGROUND:Patients diagnosed with Crohn disease (CD) are known to be at an increased risk of bowel cancers and lymphoma. CD is an autoimmune disease and we hypothesize that the patients are predisposed to a wider spectrum of cancers. PATIENTS AND METHODS: A CD research database was constructed by identifying hospitalized CDpatients from the Hospital Discharge Register and cancerpatients from the Swedish Cancer Registry. Follow-up of 21 788 CDpatients first hospitalized during the years 1964-2004 identified 1424 cancer cases. Standardized incidence ratios (SIRs) were calculated by comparing cancers in CDpatients with subjects without CD. RESULTS: In addition to the known sites, many additional sites were in excess in CDpatients. These included liver, pancreatic, lung, prostate, testicular, kidney and skin (squamous cell) cancers; nonthyroid endocrine tumors and leukemia. The previously established sites showed the highest SIRs; however, SIRs >2.0 were noted for the novel sites of the liver, testis and kidney. For testicular cancer, the SIR of seminoma was 2.74. Cancer risks were influences by age at first hospitalization for CD but whether the age effects were increasing or decreasing depending on the cancer type. CONCLUSIONS: This large study identified many novel subsequent cancers in CDpatients.
Authors: Elizabeth A Tindall; Hoa N Hoang; Melissa C Southey; Dallas R English; John L Hopper; Graham G Giles; Gianluca Severi; Vanessa M Hayes Journal: BMC Cancer Date: 2010-02-25 Impact factor: 4.430
Authors: Fangcheng Yuan; Rayjean J Hung; Naomi Walsh; Han Zhang; Elizabeth A Platz; William Wheeler; Lei Song; Alan A Arslan; Laura E Beane Freeman; Paige Bracci; Federico Canzian; Mengmeng Du; Steven Gallinger; Graham G Giles; Phyllis J Goodman; Charles Kooperberg; Loic Le Marchand; Rachel E Neale; Jonas Rosendahl; Ghislaine Scelo; Xiao-Ou Shu; Kala Visvanathan; Emily White; Wei Zheng; Demetrius Albanes; Pilar Amiano; Gabriella Andreotti; Ana Babic; William R Bamlet; Sonja I Berndt; Paul Brennan; Bas Bueno-de-Mesquita; Julie E Buring; Peter T Campbell; Stephen J Chanock; Charles S Fuchs; J Michael Gaziano; Michael G Goggins; Thilo Hackert; Patricia Hartge; Manal M Hassan; Elizabeth A Holly; Robert N Hoover; Verena Katzke; Holger Kirsten; Robert C Kurtz; I-Min Lee; Nuria Malats; Roger L Milne; Neil Murphy; Kimmie Ng; Ann L Oberg; Miquel Porta; Kari G Rabe; Francisco X Real; Nathaniel Rothman; Howard D Sesso; Debra T Silverman; Ian M Thompson; Jean Wactawski-Wende; Xiaoliang Wang; Nicolas Wentzensen; Lynne R Wilkens; Herbert Yu; Anne Zeleniuch-Jacquotte; Jianxin Shi; Eric J Duell; Laufey T Amundadottir; Donghui Li; Gloria M Petersen; Brian M Wolpin; Harvey A Risch; Kai Yu; Alison P Klein; Rachael Stolzenberg-Solomon Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie Journal: World J Gastroenterol Date: 2015-04-07 Impact factor: 5.742
Authors: Annelie M Landgren; Ola Landgren; Gloria Gridley; Graça M Dores; Martha S Linet; Lindsay M Morton Journal: Cancer Date: 2010-11-02 Impact factor: 6.860
Authors: Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin Journal: Haematologica Date: 2010-01-06 Impact factor: 9.941
Authors: Travis J Meyers; Adam B Weiner; Rebecca E Graff; Anuj S Desai; Lauren Folgosa Cooley; William J Catalona; Stephen B Hanauer; Jennifer D Wu; Edward M Schaeffer; Sarki A Abdulkadir; Shilajit D Kundu; John S Witte Journal: Int J Cancer Date: 2020-05-29 Impact factor: 7.396